Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).

ABSTRACT:

Aims/introduction

Tofogliflozin is a potent and highly selective sodium-glucose cotransporter 2 inhibitor, and is currently used to treat patients with type 2 diabetes mellitus. We designed a 3-year study of tofogliflozin in patients with type 2 diabetes mellitus to evaluate the safety and effectiveness in routine clinical practice. The 3- and 12-month interim analysis showed tofogliflozin was well-tolerated, safe and clinically effective. Here, we report the results of the 24-month interim analysis.

Materials and methods

This is a 3-year prospective, observational and multicenter post-marketing study (Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients/Long Term).

Results

Of the 6,897 patients enrolled, 6,712 and 6,461 patients were analyzed for th

SUBMITTER: Utsunomiya K 

PROVIDER: S-EPMC7378444 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature